Skip to content

Author

Montaha Al-Iede

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Global, regional, and national prevalence of second-hand smoke and attributable disease burden in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

BACKGROUND Second-hand smoke (SHS) exposure remains a major source of morbidity and mortality among non-smokers. This study presents the first dedicated Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) publication to systematically quantify SHS prevalence and evaluate its effect as a global risk factor across a broader range of outcomes. METHODS Using the GBD 2023 comparative risk assessment framework, we estimated SHS exposure prevalence and attributable disease burden across 204 countries and territories from 1990 to 2023, stratified by age and sex. Exposure estimates were derived by synthesising population-based surveys and household composition data through spatiotemporal Gaussian process regression. Relative risks for nine health outcomes, now including asthma, were estimated using the Burden of Proof methodology, and applied to calculate attributable deaths and disability-adjusted life-years (DALYs). FINDINGS In 2023, an estimated 2·71 billion (95% UI 2·44-3·02) people worldwide were exposed to SHS, including 767 million (687-858) children aged 0-14 years. Age-standardised prevalence was highest in southeast Asia, east Asia, and Oceania (48·4% [44·0-53·4]), with female individuals in some countries experiencing nearly 1·8 times the exposure prevalence of male individuals. Despite a 22·2% (10·6-32·4) decline in global age-standardised prevalence since 1990, this progress has not been sufficient to reduce the absolute number of exposed individuals, which has remained stable globally and has risen sharply in sub-Saharan Africa (98·5% [62·0-144·4] increase) and North Africa and the Middle East (72·1% [47·8-101·8] increase). In 2023, SHS exposure accounted for 1·66 million (1·33-2·07) deaths and 44·8 million (35·8-54·3) DALYs globally. Ischaemic heart disease was the leading contributor to SHS-attributable DALYs (12·0 million [9·31-15·2]) overall, while lower respiratory infections predominated among children (5·16 million [3·48-7·12]). INTERPRETATION We estimated that SHS remains a substantial driver of global health loss, particularly through cardiovascular and paediatric respiratory diseases. Persistent geographical disparities and growing absolute numbers of exposed individuals in several regions underscore the urgent need for accelerated implementation and enforcement of comprehensive tobacco control measures, particularly to protect women and children in both public and domestic environments. FUNDING Bloomberg Philanthropies and the Gates Foundation.

Luisa S. Flor, Jason A Anderson, Brooks W. Morgan et al. · 0 citations
Jul 2026

Clinical characteristics and co-infection patterns of human metapneumovirus infection in children under 5 years of age.

OBJECTIVE Human metapneumovirus (HMPV) is a significant cause of acute respiratory tract infections (ARTIs) in young children. This study aimed to describe the clinical characteristics, co-infection patterns, and seasonal trends of HMPV in children under 5 years of age. METHODS This retrospective study included pediatric patients under 5 years old admitted to Jordan University Hospital (JUH) between October 2014 and May 2024 with PCR-confirmed HMPV infection. Demographic, clinical, laboratory, and outcome data were extracted from medical records. RESULTS A total of 109 pediatric patients were diagnosed with HMPV. The most frequent symptoms were fever (75%), difficulty breathing (72%), and feeding difficulties (68%), while common clinical signs included dyspnea (63%), abnormal chest sounds (60%), and retractions (45%). Co-infection was significantly associated with prematurity (p = 0.039). Patients with isolated HMPV infections were more likely to receive nebulized therapy (p = 0.020), whereas those with co-infections more frequently required high-flow nasal cannula support (p = 0.007). Rhinovirus, RSV, and bocavirus were the most commonly detected co-pathogens. Most HMPV cases occurred between January and April. CONCLUSIONS HMPV represents a significant cause of pediatric respiratory illness. Co-infections were frequent and associated with increased respiratory support requirements. These findings enhance understanding of HMPV's clinical presentation and outcomes.

Montaha Al-Iede, Yasmeen R Olimat, Leen M Alhadidi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.